دورية أكاديمية
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
| العنوان: | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. |
|---|---|
| المؤلفون: | Hecht JR; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: JRHecht@mednet.ucla.edu., Douillard JY; Integrated Centres of Oncology R. Gauducheau and University of Nantes, Nantes, France., Schwartzberg L; University of Tennessee Health Science Center, Memphis, TN, USA., Grothey A; Mayo Clinic, Rochester, MN, USA., Kopetz S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rong A; Amgen Inc., Thousand Oaks, CA, USA., Oliner KS; Amgen Inc., Thousand Oaks, CA, USA., Sidhu R; Amgen Inc., Thousand Oaks, CA, USA. |
| المصدر: | Cancer treatment reviews [Cancer Treat Rev] 2015 Sep; Vol. 41 (8), pp. 653-9. Date of Electronic Publication: 2015 May 21. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Amsterdam : Elsevier Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology, Antibodies, Monoclonal/*therapeutic use , Antibodies, Monoclonal, Humanized/*therapeutic use , ErbB Receptors/*antagonists & inhibitors , GTP Phosphohydrolases/*genetics , Membrane Proteins/*genetics , Proto-Oncogene Proteins/*genetics , ras Proteins/*genetics, Antineoplastic Agents/therapeutic use ; Cetuximab ; Humans ; Mutation ; Neoplasm Metastasis ; Panitumumab ; Pharmacogenetics ; Prognosis ; Proto-Oncogene Proteins p21(ras) ; Treatment Outcome |
| مستخلص: | RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations—including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4—can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment. (Copyright © 2015. Published by Elsevier Ltd.) |
| فهرسة مساهمة: | Keywords: Biomarker; Cetuximab; EGFR; Metastatic colorectal cancer; Panitumumab; RAS mutation |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (Antineoplastic Agents) 0 (KRAS protein, human) 0 (Membrane Proteins) 0 (Proto-Oncogene Proteins) 6A901E312A (Panitumumab) EC 2.7.10.1 (ErbB Receptors) EC 3.6.1.- (GTP Phosphohydrolases) EC 3.6.1.- (NRAS protein, human) EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) EC 3.6.5.2 (ras Proteins) PQX0D8J21J (Cetuximab) |
| تواريخ الأحداث: | Date Created: 20150730 Date Completed: 20151106 Latest Revision: 20220408 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.ctrv.2015.05.008 |
| PMID: | 26220150 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-1967 |
|---|---|
| DOI: | 10.1016/j.ctrv.2015.05.008 |